AI Summary
This article discusses the development of a therapeutic polymer-based cannabidiol (CBD) formulation aimed at addressing neuroinflammation linked to ischemic events in the brain. The study likely focuses on the potential benefits of using this novel formulation to reduce inflammation and protect brain tissue following ischemic incidents, with implications for improved stroke treatment or prevention. Summary unavailable.
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.3c00244